Lixte Biotechnology Holdings Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-39717 LIXTE BIOTECHNOLOGY HOLDINGS, INC. 20-2903526(I.R.S. EmployerIdentification Number) (State or other jurisdiction ofincorporation or organization) 433 Plaza Real, Suite 275Boca Raton, FL 33432(Address of principal executive offices, including Zip Code) (631) 830-7092(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”,and “emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☐ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of May 12, 2026, the Company had 12,382,944 shares of common stock issued and outstanding. LIXTE BIOTECHNOLOGY HOLDINGS, INC.AND SUBSIDIARY TABLE OF CONTENTSPageNumberPART I - FINANCIAL INFORMATION3Item 1. Condensed Consolidated Financial Statements3Condensed Consolidated Balance Sheets – March 31, 2026 (Unaudited) and December 31, 20253Condensed Consolidated Statements of Operations (Unaudited) – Three Months Ended March 31, 2026 and 20254Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) – Three Months Ended March 31, 2026 and 20255Condensed Consolidated Statements of Cash Flows (Unaudited) – Three Months Ended March 31, 2026 and 20256Notes to Condensed Consolidated Financial Statements (Unaudited) – Three Months Ended March 31, 2026 and 20257Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations31Item 3. Quantitative and Qualitative Disclosures About Market Risk38Item 4. Controls and Procedures38PART II - OTHER INFORMATION39Item 1. Legal Proceedings39Item 1A. Risk Factors39Item 2. Unregistered Sales of Equity Securities and Use of Proceeds39Item 3. Defaults Upon Senior Securities39Item 4. Mine Safety Disclosures39Item 5. Other Information39Item 6. Exhibits40SIGNATURES412 PART I - FINANCIAL INFORMATION ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS LIXTE BIOTECHNOLOGY HOLDINGS, INC.AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS LIXTE BIOTECHNOLOGY HOLDINGS, INC.AND SUBSIDIARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited) LIXTE BIOTECHNOLOGY HOLDINGS, INC.AND SUBSIDIARY LIXTE BIOTECHNOLOGY HOLDINGS, INC.AND SUBSIDIARY CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited) LIXTE BIOTECHNOLOGY HOLDINGS, INC.AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Three Months Ended March 31, 2026 and 2025 1. Organization and Basis of Presentation The unaudited condensed consolidated financial statements as of March 31, 2026, and for the three months ended March 31, 2026 and2025, of Lixte Biotechnology Holdings, Inc. (a Delaware corporation), include the accounts of Lixte Biotechnology, Inc. (a wholly-ownedDelaware corporation), and Liora Technologies Europe Ltd. (“Liora”, an 80% owned corporation organized under the laws of England andWales) (collectively, the “Company”). In the opinion of management of the Company, all adjustments, including normal recurring accruals, have been made that arenecessary to present fairly the financial position of the Company as of March 31, 2026, and the results of its operations for the three monthsended March 31, 2026, and its cash flows for the three months ended March 31, 2026. Operating results for the interim periods presented arenot necessarily indicative of the results to be expected for a full fiscal year. The condensed consol